Synthace

Synthace
Name	Synthace
Type	Private
Industry	Biotechnology software
Founded	2012
Founders	Andrew Hollingsworth, Amir Banaei, Ian Sore
Headquarters	London
Products	Antha

Synthace is a biotechnology software company that developed Antha, a laboratory automation and experimental design platform intended to standardize, reproduce, and scale wet lab workflows. The company positioned itself at the intersection of laboratory informatics, synthetic biology, and automation, aiming to link experimental abstraction to robotic execution for researchers in academic, industrial, and contract-research settings. Synthace’s work engaged with institutions and firms across the life sciences ecosystem to address reproducibility, throughput, and integration challenges.

History

Founded in 2012 by the engineers Andrew Hollingsworth, Amir Banaei, and Ian Sore, the company emerged during a period of rapid growth in synthetic biology, bioinformatics, and laboratory automation. Early activity connected to incubators and accelerators in London and interactions with research groups at Imperial College London, University College London, and the Wellcome Trust ecosystem. Over the 2010s Synthace iterated its platform amid broader industry developments involving companies such as Illumina, Thermo Fisher Scientific, and automation integrators like Hamilton Company and Tecan. The company announced commercial deployments and expanded its team as synthetic biology startups and contract research organizations sought digital solutions to scale workflows. Strategic milestones included product launches, funding rounds with venture investors, and pilot programs with academic and industrial laboratories.

Products and Technology

Synthace’s core product, Antha, combined a domain-specific language for describing protocols with orchestration software to translate designs into executable instructions on automation hardware. The technology integrated protocol representation, version control, experiment design, and run-time orchestration compatible with liquid handlers and instruments from vendors such as Hamilton Company, Tecan, and Beckman Coulter. Antha emphasized abstraction layers that separated high-level experimental intent from low-level device commands, aligning with ideas from laboratory automation practice and informatics projects like Electronic Lab Notebook initiatives. The platform supported computational elements including algorithmic design of experiments, parameter sweeping, and conditional logic, allowing tighter coupling between computational biology tools—from packages inspired by work at European Bioinformatics Institute and EMBL—and physical execution in the lab. Synthace also focused on reproducibility features such as audit trails, metadata capture, and integration with laboratory information management systems used at institutions like Cambridge University Hospitals and industrial partners.

Applications and Use Cases

Users applied the platform across domains including gene synthesis, DNA assembly workflows (e.g., Golden Gate, Gibson assembly), high-throughput screening, cell culture protocols, and enzyme engineering campaigns. Academic groups in synthetic biology and industrial teams in pharmaceutical industry and biotechnology used the system to accelerate design-build-test cycles, with deployment scenarios in research laboratories, contract development and manufacturing organizations, and partner automation facilities. Use cases involved integration with sequence design tools from groups around MIT and Harvard, scaling assays related to CRISPR workflows and supporting strain engineering projects similar to efforts at Ginkgo Bioworks and Zymergen. The platform also supported protocol standardization initiatives promoted by consortia influenced by organizations like ELIXIR and standards communities tied to the Global Alliance for Genomics and Health.

Business Model and Funding

Synthace operated on a software-as-a-service and licensing model targeting biotechnology companies, academic core facilities, and contract research organizations. Revenue streams combined subscription fees for the Antha platform, professional services for integration with automation hardware, and custom engineering engagements. The company raised venture capital and private funding from investors that included life-science–focused firms and technology investors participating in rounds during the 2010s and early 2020s. Funding rounds were reported alongside comparable market activity involving venture-backed firms such as Benchling, Inscripta, and Zymergen, reflecting investor interest in lab automation and informatics. Strategic commercial engagements sometimes included joint development agreements and pilot projects that served as proofs of concept prior to wider deployment.

Partnerships and Collaborations

Synthace engaged with a range of partners spanning instrument vendors, academic laboratories, contract research organizations, and industry players. Collaborations with automation manufacturers like Tecan and Hamilton Company enabled device integrations; partnerships with academic laboratories at Imperial College London and University College London supported method validation and user feedback. The company worked with contract research organizations and biotechnology firms to implement production-level workflows, mirroring cooperative models used by firms such as Eurofins and Charles River Laboratories. In some cases Synthace participated in consortia and standards discussions with entities including ELIXIR and prominent research funders to align with reproducibility and data-sharing objectives.

Criticisms and Controversies

Critiques of Synthace centered on questions familiar to the laboratory automation and software-instrumentation space: the complexity and cost of integrating heterogeneous automation ecosystems, vendor lock-in concerns, and the challenge of translating bespoke wet-lab tacit knowledge into formalized protocols. Observers compared integration hurdles to those experienced by users of platforms from Benchling and Labcyte and raised issues about interoperability with legacy equipment in core facilities at institutions such as Oxford University and Imperial College London. Debates also touched on broader ethical and governance themes in synthetic biology debated at venues like the Asilomar Conference and regulatory dialogues involving agencies such as the UK Research and Innovation and regulatory frameworks in the European Union. Some academic users pointed to the learning curve for experimentalists accustomed to manual bench techniques and the need for sustained support to realize promised reproducibility gains.

Category:Biotechnology companies